Landos Biopharma, Inc.
LABP · NASDAQ
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.08 | -0.17 | -0.02 | 0.06 |
| FCF Yield | -6.34% | -21.87% | -9.25% | -19.55% |
| EV / EBITDA | -11.30 | 2.35 | 3.52 | 4.07 |
| Quality | ||||
| ROIC | -40.14% | -19.85% | -13.80% | -10.26% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.96 | 0.81 | 0.38 | 1.30 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -71.02% | -123.03% | 56.40% | 37.45% |
| Safety | ||||
| Net Debt / EBITDA | 3.13 | 5.95 | 8.16 | 10.01 |
| Interest Coverage | 0.00 | -11.56 | 0.00 | -7.97 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |